PL2978845T3 - Zmodyfikowane oligonukleotydy tgf-beta - Google Patents

Zmodyfikowane oligonukleotydy tgf-beta

Info

Publication number
PL2978845T3
PL2978845T3 PL14713467T PL14713467T PL2978845T3 PL 2978845 T3 PL2978845 T3 PL 2978845T3 PL 14713467 T PL14713467 T PL 14713467T PL 14713467 T PL14713467 T PL 14713467T PL 2978845 T3 PL2978845 T3 PL 2978845T3
Authority
PL
Poland
Prior art keywords
modified tgf
oligonucleotides
beta
beta oligonucleotides
tgf
Prior art date
Application number
PL14713467T
Other languages
English (en)
Inventor
Frank Jaschinski
Michel JANICOT
Eugen Uhlmann
Original Assignee
Isarna Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isarna Therapeutics Gmbh filed Critical Isarna Therapeutics Gmbh
Publication of PL2978845T3 publication Critical patent/PL2978845T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/323Chemical structure of the sugar modified ring structure
    • C12N2310/3231Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/34Spatial arrangement of the modifications
    • C12N2310/341Gapmers, i.e. of the type ===---===
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epidemiology (AREA)
PL14713467T 2013-03-27 2014-03-27 Zmodyfikowane oligonukleotydy tgf-beta PL2978845T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP13161474 2013-03-27
EP13173078 2013-06-20
EP13199826 2013-12-30
EP14713467.0A EP2978845B8 (en) 2013-03-27 2014-03-27 Modified tgf-beta oligonucleotides
PCT/EP2014/056221 WO2014154835A2 (en) 2013-03-27 2014-03-27 Modified tgf-beta oligonucleotides

Publications (1)

Publication Number Publication Date
PL2978845T3 true PL2978845T3 (pl) 2020-11-16

Family

ID=50390096

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14713467T PL2978845T3 (pl) 2013-03-27 2014-03-27 Zmodyfikowane oligonukleotydy tgf-beta

Country Status (14)

Country Link
US (2) US9926563B2 (pl)
EP (1) EP2978845B8 (pl)
JP (1) JP6492053B2 (pl)
KR (1) KR102108599B1 (pl)
CN (2) CN109234274B (pl)
BR (1) BR112015024764B1 (pl)
CA (1) CA2908096C (pl)
DK (1) DK2978845T3 (pl)
EA (1) EA201591590A1 (pl)
ES (1) ES2808862T3 (pl)
HK (1) HK1221253A1 (pl)
PL (1) PL2978845T3 (pl)
PT (1) PT2978845T (pl)
WO (1) WO2014154835A2 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180103817A (ko) 2016-02-09 2018-09-19 오토텔릭 엘엘씨 암을 치료하기 위한 조성물과 방법
US9758786B2 (en) 2016-02-09 2017-09-12 Autotelic, Llc Compositions and methods for treating pancreatic cancer
KR101843984B1 (ko) 2016-02-09 2018-03-30 오토텔릭 엘엘씨 췌장암을 치료하기 위한 조성물과 방법
MA45471A (fr) * 2016-04-01 2019-02-06 Avidity Biosciences Llc Acides nucléiques de phosphatidylinositol-3-kinase et leurs utilisations
MA45340A (fr) * 2016-04-01 2019-02-06 Avidity Biosciences Llc Acides nucléiques du récepteur des androgènes et leurs utilisations
MA45469A (fr) * 2016-04-01 2019-02-06 Avidity Biosciences Llc Acides nucléiques de bêta-caténine et leurs utilisations
MA45349A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Acides nucléiques egfr et leurs utilisations
MA45468A (fr) * 2016-04-01 2019-02-06 Avidity Biosciences Llc Acides nucléiques myc et utilisations
MA45470A (fr) * 2016-04-01 2019-02-06 Avidity Biosciences Llc Acides nucléiques kras et leurs utilisations
MA45328A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
WO2018087359A1 (en) * 2016-11-11 2018-05-17 Isarna Therapeutics Gmbh Tgf-beta oligonucleotide for use in treatment of ophthalmic diseases
AU2018378812A1 (en) 2017-12-06 2020-07-09 Avidity Biosciences, Inc. Compositions and methods of treating muscle atrophy and myotonic dystrophy
IL296387B1 (en) 2020-03-19 2024-04-01 Avidity Biosciences Inc Preparations and methods for the treatment of facial, back and arm muscle atrophy
WO2022060208A1 (ko) * 2020-09-21 2022-03-24 오토텔릭바이오 주식회사 안티센스 올리고뉴클레오타이드
CN113073082A (zh) * 2021-03-19 2021-07-06 广州远想生物科技有限公司 TGF-β3间充质干细胞外泌体及其制备方法和应用
KR20240055874A (ko) 2021-09-16 2024-04-29 어비디티 바이오사이언시스 인크. 안면견갑상완 근이영양증을 치료하는 조성물 및 방법
KR20230063290A (ko) * 2021-11-01 2023-05-09 오토텔릭바이오 주식회사 안티센스 올리고뉴클레오타이드

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4309406A (en) 1979-07-10 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4309404A (en) 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4704295A (en) 1983-09-19 1987-11-03 Colorcon, Inc. Enteric film-coating compositions
US4556552A (en) 1983-09-19 1985-12-03 Colorcon, Inc. Enteric film-coating compositions
AU6794594A (en) 1993-04-30 1994-11-21 Biognostik Gesellschaft Fur Biomolekulare Diagnostik Mbh Antisense-oligonucleotides for the treatment of immunosuppressive effects of transforming growth factor-beta (tgf-beta )
EP0695354B1 (en) 1993-04-30 2002-01-09 BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH Antisense-oligonucleotides for the treatment of immunosuppressive effects of transforming growth factor-beta1 (tgf-beta1)
US20050287128A1 (en) 2001-05-18 2005-12-29 Sirna Therapeutics, Inc. RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA)
WO2003070197A2 (en) 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF TGF-BETA AND TGF-BETA RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20040006030A1 (en) 2002-07-02 2004-01-08 Isis Pharmaceuticals Inc. Antisense modulation of TGF-beta 2 expression
AU2003225495B2 (en) 2002-04-05 2009-01-15 Roche Innovation Center Copenhagen A/S Oligomeric compounds for the modulation HIF-1alpha expression
JP4476594B2 (ja) * 2003-10-17 2010-06-09 淳二 城戸 有機エレクトロルミネッセント素子
KR20070006709A (ko) 2003-12-23 2007-01-11 산타리스 팔마 에이/에스 Bcl-2의 조절을 위한 올리고머 화합물
EP1568383A3 (en) * 2004-02-27 2005-11-16 Antisense Pharma GmbH Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment
AU2005218759B2 (en) * 2004-02-27 2009-07-16 Antisense Pharma Gmbh Pharmaceutical composition
EP1935428A1 (en) 2006-12-22 2008-06-25 Antisense Pharma GmbH Oligonucleotide-polymer conjugates
EP2155877A2 (en) 2007-05-11 2010-02-24 Santaris Pharma A/S Rna antagonist compounds for the modulation of her3
US20110119781A1 (en) * 2008-07-15 2011-05-19 Birgit Bramlage Compositions and Methods for Inhibiting Expression of TGF-BETA Receptor Genes
WO2011154542A1 (en) * 2010-06-11 2011-12-15 Artisense Pharma Gmbh Method for selective oligonucleotide modification
EP2453017A1 (en) 2010-11-12 2012-05-16 Antisense Pharma GmbH Oligonucleotides for use in prophylaxis and/or treatment of TGF-beta1 and TGF-beta2, TGF-beta2 and TGF-beta3, TGF-beta1 and TGF-beta3, or TGF-beta1, TGF-beta2, and TGF-beta3 mRNA overexpressing diseases
SG11201407486PA (en) 2012-05-16 2014-12-30 Rana Therapeutics Inc Compositions and methods for modulating utrn expression

Also Published As

Publication number Publication date
CA2908096A1 (en) 2014-10-02
DK2978845T3 (da) 2020-08-10
WO2014154835A2 (en) 2014-10-02
US9926563B2 (en) 2018-03-27
CN109234274A (zh) 2019-01-18
EA201591590A1 (ru) 2016-05-31
US20180230473A1 (en) 2018-08-16
JP2016515385A (ja) 2016-05-30
KR20150140701A (ko) 2015-12-16
BR112015024764A2 (pt) 2017-10-24
US20160076037A1 (en) 2016-03-17
CN105378083B (zh) 2018-09-21
CA2908096C (en) 2022-05-03
EP2978845B8 (en) 2020-06-17
US10538768B2 (en) 2020-01-21
JP6492053B2 (ja) 2019-03-27
HK1221253A1 (zh) 2017-05-26
CN105378083A (zh) 2016-03-02
KR102108599B1 (ko) 2020-05-08
EP2978845B1 (en) 2020-04-29
ES2808862T3 (es) 2021-03-02
CN109234274B (zh) 2021-09-21
EP2978845A2 (en) 2016-02-03
WO2014154835A3 (en) 2014-11-20
BR112015024764B1 (pt) 2022-06-28
PT2978845T (pt) 2020-08-03

Similar Documents

Publication Publication Date Title
HK1221253A1 (zh) 修飾的 -β寡核苷酸
EP3069966A4 (en) VEHICLE
AP2015008951A0 (en) Vehicle
PL2978844T3 (pl) Modyfikowane oligonukleotydy tgf-beta2
AU352451S (en) Sterilizer
AU351612S (en) Vehicle
AP2015008947A0 (en) Vehicle
AP2015008946A0 (en) Vehicle
AP2015008942A0 (en) Vehicle
AP2015008943A0 (en) Vehicle
AP2015008944A0 (en) Vehicle
AP2015008939A0 (en) Vehicle
GB201322972D0 (en) Vehicle
GB201305495D0 (en) Vehicle
EP3072781A4 (en) VEHICLE
GB201312706D0 (en) Vehicle
EP3069960A4 (en) VEHICLE
AP2015008941A0 (en) Vehicle
AP2015008949A0 (en) Vehicle
EP2987675A4 (en) VEHICLE
AP2015008945A0 (en) Vehicle
EP3025915A4 (en) VEHICLE
EP3000706A4 (en) VEHICLE
EP3006312A4 (en) VEHICLE
GB201315714D0 (en) DNA Construct